Time to start watching for data release!
$Adlai Nortye (ANL.US)$
AN4005
· In an ongoing Phase 1 study (NCT04999384), the Company is investigating the safety of AN4005, its oral small-molecule PD-L1 inhibitor.
· The Company plans to provide a clinical update in the second half of 2024.
· The expansion cohort portion of the trial for IO treatment-naïve patients was initiated in July 2024.
AN4005
· In an ongoing Phase 1 study (NCT04999384), the Company is investigating the safety of AN4005, its oral small-molecule PD-L1 inhibitor.
· The Company plans to provide a clinical update in the second half of 2024.
· The expansion cohort portion of the trial for IO treatment-naïve patients was initiated in July 2024.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
